Physician profile
Chris Ullrich
NPI 1679544688
$5,683.05
in general payments reported to CMS, 2019-2025
22 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,838 · 2020: $484 · 2021: $577 · 2022: $473 · 2023: $674 · 2024: $993 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Honoraria: $32.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.33 |
| Honoraria | $32.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,078.06 | 2019-2025 | Clareon, Unity, Argos |
| Johnson & Johnson Surgical Vision, INC. | $1,312.28 | 2019-2025 | Tecnis Simplicity |
| Rxsight INC | $604.66 | 2022-2025 | Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Glaukos Corporation | $341.73 | 2019-2025 | Idosetr, Idose, Istent Infinite |
| Biotissue Holdings INC. | $237.78 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $231.82 | 2023-2025 | Vyzulta, Miebo, Lotemax Sm |
| Allergan, INC. | $216.64 | 2019-2020 | |
| Abbvie INC. | $193.04 | 2023-2025 | Alphagan P, Lumigan |
| Kala Pharmaceuticals, INC. | $82.73 | 2019 | |
| Thea Pharma INC. | $62.75 | 2024-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $60.95 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.03 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $32.53 | 2025 | Xdemvy |
| Regeneron Healthcare Solutions, INC. | $28.84 | 2022 | |
| Amgen INC. | $24.53 | 2025 | Tepezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $23.51 | 2024 | Ryzumvi, Tyrvaya |
| Sun Pharmaceutical Industries INC. | $21.11 | 2019 | |
| Dompe US, INC. | $21.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.15 | 2021 | |
| Rayner Intraocular Lenses Limited | $15.66 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Optos, INC. | $15.60 | 2022 | |
| Eyepoint US, INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chris Ullrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.